Target Gene/Pathway Pathway / Gene

  

Search results

No. KEGG PATHWAY
On map, Yellow: Drug target, Red: All disease-related 		KEGG GENES KEGG DRUG DrugBank Disease ID
1 African trypanosomiasis 💬
 [1] IL1B 💬 D09315 💬 Canakinumab [10] 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
2 African trypanosomiasis 💬
 [1] IL1B 💬 D06635 💬 Rilonacept [4] 51, 106, 107, 266 💬
3 AGE-RAGE signaling pathway in diabetic complications 💬
 [2] IL1A, IL1B 💬 D06635 💬 Rilonacept [4] 51, 106, 107, 266 💬
4 AGE-RAGE signaling pathway in diabetic complications 💬
 [1] IL1B 💬 D09315 💬 Canakinumab [10] 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
5 Alcoholic liver disease 💬
 [1] IL1B 💬 D09315 💬 Canakinumab [10] 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
6 Alcoholic liver disease 💬
 [1] IL1B 💬 D06635 💬 Rilonacept [4] 51, 106, 107, 266 💬
7 Alzheimer disease 💬
 [2] IL1A, IL1B 💬 D06635 💬 Rilonacept [4] 51, 106, 107, 266 💬
8 Alzheimer disease 💬
 [1] IL1B 💬 D09315 💬 Canakinumab [10] 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
9 Alzheimer disease 💬
 [9] TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8 💬 D00570 💬 Colchicine [7]  2 , 42, 46, 56, 93, 210, 266 💬
10 Amoebiasis 💬
 [1] IL1B 💬 D09315 💬 Canakinumab [10] 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
11 Amoebiasis 💬
 [1] IL1B 💬 D06635 💬 Rilonacept [4] 51, 106, 107, 266 💬
12 Amoebiasis 💬
 [2] IL1R1, IL1R2 💬 D02934 💬 Anakinra [18]  2 , 13, 15, 28, 37, 41, 46, 49, 50, 56, 65, 84, 86, 97, 106, 107, 266, 299 💬
13 Amyotrophic lateral sclerosis 💬
 [9] TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8 💬 D00570 💬 Colchicine [7]  2 , 42, 46, 56, 93, 210, 266 💬
14 Antifolate resistance 💬
 [1] IL1B 💬 D09315 💬 Canakinumab [10] 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
15 Antifolate resistance 💬
 [1] IL1B 💬 D06635 💬 Rilonacept [4] 51, 106, 107, 266 💬
16 C-type lectin receptor signaling pathway 💬
 [1] IL1B 💬 D09315 💬 Canakinumab [10] 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
17 C-type lectin receptor signaling pathway 💬
 [1] IL1B 💬 D06635 💬 Rilonacept [4] 51, 106, 107, 266 💬
18 Cellular senescence 💬
 [1] IL1A 💬 D06635 💬 Rilonacept [4] 51, 106, 107, 266 💬
19 Chagas disease 💬
 [1] IL1B 💬 D09315 💬 Canakinumab [10] 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
20 Chagas disease 💬
 [1] IL1B 💬 D06635 💬 Rilonacept [4] 51, 106, 107, 266 💬
21 Coronavirus disease - COVID-19 💬
 [1] IL1B 💬 D09315 💬 Canakinumab [10] 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
22 Coronavirus disease - COVID-19 💬
 [1] IL1B 💬 D06635 💬 Rilonacept [4] 51, 106, 107, 266 💬
23 Coronavirus disease - COVID-19 💬
 [1] IL6R 💬 D02596 💬 Tocilizumab [21]  2 , 11, 13, 40, 41, 42, 43, 44, 46, 49, 50, 51, 53, 54, 55, 56, 86, 107, 266, 271, 331 💬
24 Cytokine-cytokine receptor interaction 💬
 [2] IL1A, IL1B 💬 D06635 💬 Rilonacept [4] 51, 106, 107, 266 💬
25 Cytokine-cytokine receptor interaction 💬
 [1] IL1B 💬 D09315 💬 Canakinumab [10] 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
26 Cytokine-cytokine receptor interaction 💬
 [2] IL1R1, IL1R2 💬 D02934 💬 Anakinra [18]  2 , 13, 15, 28, 37, 41, 46, 49, 50, 56, 65, 84, 86, 97, 106, 107, 266, 299 💬
27 Cytokine-cytokine receptor interaction 💬
 [1] IL6R 💬 D02596 💬 Tocilizumab [21]  2 , 11, 13, 40, 41, 42, 43, 44, 46, 49, 50, 51, 53, 54, 55, 56, 86, 107, 266, 271, 331 💬
28 Cytosolic DNA-sensing pathway 💬
 [1] IL1B 💬 D09315 💬 Canakinumab [10] 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
29 Cytosolic DNA-sensing pathway 💬
 [1] IL1B 💬 D06635 💬 Rilonacept [4] 51, 106, 107, 266 💬
30 EGFR tyrosine kinase inhibitor resistance 💬
 [1] IL6R 💬 D02596 💬 Tocilizumab [21]  2 , 11, 13, 40, 41, 42, 43, 44, 46, 49, 50, 51, 53, 54, 55, 56, 86, 107, 266, 271, 331 💬
31 Fluid shear stress and atherosclerosis 💬
 [2] IL1A, IL1B 💬 D06635 💬 Rilonacept [4] 51, 106, 107, 266 💬
32 Fluid shear stress and atherosclerosis 💬
 [1] IL1B 💬 D09315 💬 Canakinumab [10] 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
33 Fluid shear stress and atherosclerosis 💬
 [2] IL1R1, IL1R2 💬 D02934 💬 Anakinra [18]  2 , 13, 15, 28, 37, 41, 46, 49, 50, 56, 65, 84, 86, 97, 106, 107, 266, 299 💬
34 Gap junction 💬
 [9] TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8 💬 D00570 💬 Colchicine [7]  2 , 42, 46, 56, 93, 210, 266 💬
35 Graft-versus-host disease 💬
 [2] IL1A, IL1B 💬 D06635 💬 Rilonacept [4] 51, 106, 107, 266 💬
36 Graft-versus-host disease 💬
 [1] IL1B 💬 D09315 💬 Canakinumab [10] 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
37 Hematopoietic cell lineage 💬
 [2] IL1A, IL1B 💬 D06635 💬 Rilonacept [4] 51, 106, 107, 266 💬
38 Hematopoietic cell lineage 💬
 [1] IL1B 💬 D09315 💬 Canakinumab [10] 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
39 Hematopoietic cell lineage 💬
 [2] IL1R1, IL1R2 💬 D02934 💬 Anakinra [18]  2 , 13, 15, 28, 37, 41, 46, 49, 50, 56, 65, 84, 86, 97, 106, 107, 266, 299 💬
40 Hematopoietic cell lineage 💬
 [1] IL6R 💬 D02596 💬 Tocilizumab [21]  2 , 11, 13, 40, 41, 42, 43, 44, 46, 49, 50, 51, 53, 54, 55, 56, 86, 107, 266, 271, 331 💬
41 Herpes simplex virus 1 infection 💬
 [1] IL1B 💬 D09315 💬 Canakinumab [10] 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
42 Herpes simplex virus 1 infection 💬
 [1] IL1B 💬 D06635 💬 Rilonacept [4] 51, 106, 107, 266 💬
43 HIF-1 signaling pathway 💬
 [1] IL6R 💬 D02596 💬 Tocilizumab [21]  2 , 11, 13, 40, 41, 42, 43, 44, 46, 49, 50, 51, 53, 54, 55, 56, 86, 107, 266, 271, 331 💬
44 Human cytomegalovirus infection 💬
 [1] IL1B 💬 D09315 💬 Canakinumab [10] 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
45 Human cytomegalovirus infection 💬
 [1] IL1B 💬 D06635 💬 Rilonacept [4] 51, 106, 107, 266 💬
46 Human cytomegalovirus infection 💬
 [1] IL1R1 💬 D02934 💬 Anakinra [18]  2 , 13, 15, 28, 37, 41, 46, 49, 50, 56, 65, 84, 86, 97, 106, 107, 266, 299 💬
47 Human cytomegalovirus infection 💬
 [1] IL6R 💬 D02596 💬 Tocilizumab [21]  2 , 11, 13, 40, 41, 42, 43, 44, 46, 49, 50, 51, 53, 54, 55, 56, 86, 107, 266, 271, 331 💬
48 Human T-cell leukemia virus 1 infection 💬
 [2] IL1R1, IL1R2 💬 D02934 💬 Anakinra [18]  2 , 13, 15, 28, 37, 41, 46, 49, 50, 56, 65, 84, 86, 97, 106, 107, 266, 299 💬
49 Huntington disease 💬
 [9] TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8 💬 D00570 💬 Colchicine [7]  2 , 42, 46, 56, 93, 210, 266 💬
50 IL-17 signaling pathway 💬
 [1] IL1B 💬 D09315 💬 Canakinumab [10] 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
51 IL-17 signaling pathway 💬
 [1] IL1B 💬 D06635 💬 Rilonacept [4] 51, 106, 107, 266 💬
52 Inflammatory bowel disease 💬
 [2] IL1A, IL1B 💬 D06635 💬 Rilonacept [4] 51, 106, 107, 266 💬
53 Inflammatory bowel disease 💬
 [1] IL1B 💬 D09315 💬 Canakinumab [10] 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
54 Inflammatory mediator regulation of TRP channels 💬
 [1] IL1B 💬 D09315 💬 Canakinumab [10] 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
55 Inflammatory mediator regulation of TRP channels 💬
 [1] IL1B 💬 D06635 💬 Rilonacept [4] 51, 106, 107, 266 💬
56 Inflammatory mediator regulation of TRP channels 💬
 [1] IL1R1 💬 D02934 💬 Anakinra [18]  2 , 13, 15, 28, 37, 41, 46, 49, 50, 56, 65, 84, 86, 97, 106, 107, 266, 299 💬
57 Influenza A 💬
 [2] IL1A, IL1B 💬 D06635 💬 Rilonacept [4] 51, 106, 107, 266 💬
58 Influenza A 💬
 [1] IL1B 💬 D09315 💬 Canakinumab [10] 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
59 JAK-STAT signaling pathway 💬
 [1] IL6R 💬 D02596 💬 Tocilizumab [21]  2 , 11, 13, 40, 41, 42, 43, 44, 46, 49, 50, 51, 53, 54, 55, 56, 86, 107, 266, 271, 331 💬
60 Legionellosis 💬
 [1] IL1B 💬 D09315 💬 Canakinumab [10] 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
61 Legionellosis 💬
 [1] IL1B 💬 D06635 💬 Rilonacept [4] 51, 106, 107, 266 💬
62 Leishmaniasis 💬
 [2] IL1A, IL1B 💬 D06635 💬 Rilonacept [4] 51, 106, 107, 266 💬
63 Leishmaniasis 💬
 [1] IL1B 💬 D09315 💬 Canakinumab [10] 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
64 Lipid and atherosclerosis 💬
 [1] IL1B 💬 D09315 💬 Canakinumab [10] 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
65 Lipid and atherosclerosis 💬
 [1] IL1B 💬 D06635 💬 Rilonacept [4] 51, 106, 107, 266 💬
66 Malaria 💬
 [1] IL1B 💬 D09315 💬 Canakinumab [10] 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
67 Malaria 💬
 [1] IL1B 💬 D06635 💬 Rilonacept [4] 51, 106, 107, 266 💬
68 MAPK signaling pathway 💬
 [2] IL1A, IL1B 💬 D06635 💬 Rilonacept [4] 51, 106, 107, 266 💬
69 MAPK signaling pathway 💬
 [1] IL1B 💬 D09315 💬 Canakinumab [10] 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
70 MAPK signaling pathway 💬
 [1] IL1R1 💬 D02934 💬 Anakinra [18]  2 , 13, 15, 28, 37, 41, 46, 49, 50, 56, 65, 84, 86, 97, 106, 107, 266, 299 💬
71 Measles 💬
 [2] IL1A, IL1B 💬 D06635 💬 Rilonacept [4] 51, 106, 107, 266 💬
72 Measles 💬
 [1] IL1B 💬 D09315 💬 Canakinumab [10] 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
73 Necroptosis 💬
 [2] IL1A, IL1B 💬 D06635 💬 Rilonacept [4] 51, 106, 107, 266 💬
74 Necroptosis 💬
 [1] IL1B 💬 D09315 💬 Canakinumab [10] 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
75 NF-kappa B signaling pathway 💬
 [1] IL1B 💬 D09315 💬 Canakinumab [10] 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
76 NF-kappa B signaling pathway 💬
 [1] IL1B 💬 D06635 💬 Rilonacept [4] 51, 106, 107, 266 💬
77 NF-kappa B signaling pathway 💬
 [1] IL1R1 💬 D02934 💬 Anakinra [18]  2 , 13, 15, 28, 37, 41, 46, 49, 50, 56, 65, 84, 86, 97, 106, 107, 266, 299 💬
78 NOD-like receptor signaling pathway 💬
 [1] IL1B 💬 D09315 💬 Canakinumab [10] 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
79 NOD-like receptor signaling pathway 💬
 [1] IL1B 💬 D06635 💬 Rilonacept [4] 51, 106, 107, 266 💬
80 Non-alcoholic fatty liver disease 💬
 [2] IL1A, IL1B 💬 D06635 💬 Rilonacept [4] 51, 106, 107, 266 💬
81 Non-alcoholic fatty liver disease 💬
 [1] IL1B 💬 D09315 💬 Canakinumab [10] 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
82 Non-alcoholic fatty liver disease 💬
 [1] IL6R 💬 D02596 💬 Tocilizumab [21]  2 , 11, 13, 40, 41, 42, 43, 44, 46, 49, 50, 51, 53, 54, 55, 56, 86, 107, 266, 271, 331 💬
83 Osteoclast differentiation 💬
 [2] IL1A, IL1B 💬 D06635 💬 Rilonacept [4] 51, 106, 107, 266 💬
84 Osteoclast differentiation 💬
 [1] IL1B 💬 D09315 💬 Canakinumab [10] 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
85 Osteoclast differentiation 💬
 [1] IL1R1 💬 D02934 💬 Anakinra [18]  2 , 13, 15, 28, 37, 41, 46, 49, 50, 56, 65, 84, 86, 97, 106, 107, 266, 299 💬
86 Parkinson disease 💬
 [9] TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8 💬 D00570 💬 Colchicine [7]  2 , 42, 46, 56, 93, 210, 266 💬
87 Pathogenic Escherichia coli infection 💬
 [1] IL1B 💬 D09315 💬 Canakinumab [10] 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
88 Pathogenic Escherichia coli infection 💬
 [1] IL1B 💬 D06635 💬 Rilonacept [4] 51, 106, 107, 266 💬
89 Pathogenic Escherichia coli infection 💬
 [1] IL1R1 💬 D02934 💬 Anakinra [18]  2 , 13, 15, 28, 37, 41, 46, 49, 50, 56, 65, 84, 86, 97, 106, 107, 266, 299 💬
90 Pathogenic Escherichia coli infection 💬
 [9] TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8 💬 D00570 💬 Colchicine [7]  2 , 42, 46, 56, 93, 210, 266 💬
91 Pathways in cancer 💬
 [1] IL6R 💬 D02596 💬 Tocilizumab [21]  2 , 11, 13, 40, 41, 42, 43, 44, 46, 49, 50, 51, 53, 54, 55, 56, 86, 107, 266, 271, 331 💬
92 Pathways of neurodegeneration - multiple diseases 💬
 [2] IL1A, IL1B 💬 D06635 💬 Rilonacept [4] 51, 106, 107, 266 💬
93 Pathways of neurodegeneration - multiple diseases 💬
 [1] IL1B 💬 D09315 💬 Canakinumab [10] 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
94 Pathways of neurodegeneration - multiple diseases 💬
 [9] TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8 💬 D00570 💬 Colchicine [7]  2 , 42, 46, 56, 93, 210, 266 💬
95 Pertussis 💬
 [2] IL1A, IL1B 💬 D06635 💬 Rilonacept [4] 51, 106, 107, 266 💬
96 Pertussis 💬
 [1] IL1B 💬 D09315 💬 Canakinumab [10] 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
97 Phagosome 💬
 [9] TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8 💬 D00570 💬 Colchicine [7]  2 , 42, 46, 56, 93, 210, 266 💬
98 PI3K-Akt signaling pathway 💬
 [1] IL6R 💬 D02596 💬 Tocilizumab [21]  2 , 11, 13, 40, 41, 42, 43, 44, 46, 49, 50, 51, 53, 54, 55, 56, 86, 107, 266, 271, 331 💬
99 Prion disease 💬
 [2] IL1A, IL1B 💬 D06635 💬 Rilonacept [4] 51, 106, 107, 266 💬
100 Prion disease 💬
 [1] IL1B 💬 D09315 💬 Canakinumab [10] 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
101 Prion disease 💬
 [9] TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8 💬 D00570 💬 Colchicine [7]  2 , 42, 46, 56, 93, 210, 266 💬
102 Prostate cancer 💬
 [1] IL1R2 💬 D02934 💬 Anakinra [18]  2 , 13, 15, 28, 37, 41, 46, 49, 50, 56, 65, 84, 86, 97, 106, 107, 266, 299 💬
103 Rheumatoid arthritis 💬
 [2] IL1A, IL1B 💬 D06635 💬 Rilonacept [4] 51, 106, 107, 266 💬
104 Rheumatoid arthritis 💬
 [1] IL1B 💬 D09315 💬 Canakinumab [10] 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
105 Salmonella infection 💬
 [1] IL1B 💬 D09315 💬 Canakinumab [10] 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
106 Salmonella infection 💬
 [1] IL1B 💬 D06635 💬 Rilonacept [4] 51, 106, 107, 266 💬
107 Salmonella infection 💬
 [9] TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8 💬 D00570 💬 Colchicine [7]  2 , 42, 46, 56, 93, 210, 266 💬
108 Shigellosis 💬
 [1] IL1B 💬 D09315 💬 Canakinumab [10] 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
109 Shigellosis 💬
 [1] IL1B 💬 D06635 💬 Rilonacept [4] 51, 106, 107, 266 💬
110 Shigellosis 💬
 [1] IL1R1 💬 D02934 💬 Anakinra [18]  2 , 13, 15, 28, 37, 41, 46, 49, 50, 56, 65, 84, 86, 97, 106, 107, 266, 299 💬
111 Th17 cell differentiation 💬
 [1] IL1B 💬 D09315 💬 Canakinumab [10] 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
112 Th17 cell differentiation 💬
 [1] IL1B 💬 D06635 💬 Rilonacept [4] 51, 106, 107, 266 💬
113 Th17 cell differentiation 💬
 [1] IL1R1 💬 D02934 💬 Anakinra [18]  2 , 13, 15, 28, 37, 41, 46, 49, 50, 56, 65, 84, 86, 97, 106, 107, 266, 299 💬
114 Th17 cell differentiation 💬
 [1] IL6R 💬 D02596 💬 Tocilizumab [21]  2 , 11, 13, 40, 41, 42, 43, 44, 46, 49, 50, 51, 53, 54, 55, 56, 86, 107, 266, 271, 331 💬
115 TNF signaling pathway 💬
 [1] IL1B 💬 D09315 💬 Canakinumab [10] 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
116 TNF signaling pathway 💬
 [1] IL1B 💬 D06635 💬 Rilonacept [4] 51, 106, 107, 266 💬
117 Toll-like receptor signaling pathway 💬
 [1] IL1B 💬 D09315 💬 Canakinumab [10] 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
118 Toll-like receptor signaling pathway 💬
 [1] IL1B 💬 D06635 💬 Rilonacept [4] 51, 106, 107, 266 💬
119 Transcriptional misregulation in cancer 💬
 [1] IL1R2 💬 D02934 💬 Anakinra [18]  2 , 13, 15, 28, 37, 41, 46, 49, 50, 56, 65, 84, 86, 97, 106, 107, 266, 299 💬
120 Tuberculosis 💬
 [2] IL1A, IL1B 💬 D06635 💬 Rilonacept [4] 51, 106, 107, 266 💬
121 Tuberculosis 💬
 [1] IL1B 💬 D09315 💬 Canakinumab [10] 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
122 Type I diabetes mellitus 💬
 [2] IL1A, IL1B 💬 D06635 💬 Rilonacept [4] 51, 106, 107, 266 💬
123 Type I diabetes mellitus 💬
 [1] IL1B 💬 D09315 💬 Canakinumab [10] 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
124 Viral protein interaction with cytokine and cytokine receptor 💬
 [1] IL6R 💬 D02596 💬 Tocilizumab [21]  2 , 11, 13, 40, 41, 42, 43, 44, 46, 49, 50, 51, 53, 54, 55, 56, 86, 107, 266, 271, 331 💬
125 Yersinia infection 💬
 [1] IL1B 💬 D09315 💬 Canakinumab [10] 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
126 Yersinia infection 💬
 [1] IL1B 💬 D06635 💬 Rilonacept [4] 51, 106, 107, 266 💬

Back to top